Alumni

Event | RNA-Seq Bootcamp

rachel.mutombo@mcgill.ca — Thu, 25 Sep 2025 23:41:01 +0000

Join CDSI, QLS-MiCM and the D2R-HeDS platform for an RNA-seq Bootcamp

Inaugural Moderna-RNA Canada ARN awarded to D2R-funded researcher Professor Maria Vera Ugalde

rachel.mutombo@mcgill.ca — Thu, 25 Sep 2025 01:00:00 +0000

Montreal, September 24, 2025 – Moderna, in partnership with RNA Canada, has awarded three prizes this year to RNA researchers in Canada for their outstanding contribution to the field. D2R is proud to announce that Professor Maria Vera Ugalde has received the Discovery of the Year Award for her seminal 2024 publication in Nature Communications (Alecki et al.,). This award recognizes groundbreaking RNA discoveries made by Canadian researchers (either as a group or individually) during the past year.

Event | Cancer Translational Research Horizons 2025

rachel.mutombo@mcgill.ca — Mon, 22 Sep 2025 14:43:13 +0000

Join the 91ֱ�� Centre for Translational Research for CTR Horizons 2025

Event | AReNA "From Mission to Action"

rachel.mutombo@mcgill.ca — Fri, 19 Sep 2025 15:41:45 +0000

AReNA, Québec’s RNA Hub, is inviting everyone involved in the field of RNA in Québec—researchers, innovators, institutions, partners, anyone curious about the field, as well as experts—to att

Event | AReNA "From Mission to Action"

roberta.santangelo@mcgill.ca — Thu, 18 Sep 2025 17:32:27 +0000

AReNA, Québec’s RNA Hub, is inviting everyone involved in the field of RNA in Québec—researchers, innovators, institutions, partners, anyone curious about the field, as well as experts—to attend the event "From Mission to Action" on October 16, 2025 at the BAnQ in Montréal.

This event is intended to celebrate a year of collective impact with presentations, discussions and networking, as well as to reconnect and collectively reflect on RNA therapies in Québec.

D2R awards nearly $1.5 million to Master's and Doctoral Scholars across Canada

rachel.mutombo@mcgill.ca — Thu, 04 Sep 2025 19:27:51 +0000

Montreal, September 10, 2025 – The DNA to RNA (D2R) initiative at 91ֱ�� is proud to announce the recipients of its Master's and Doctoral Scholar Awards, recognizing outstanding and active trainees working on diverse D2R-aligned research projects.

Event | Digital Health Symposium: From Research Infrastructure to Clinical Care

roberta.santangelo@mcgill.ca — Thu, 04 Sep 2025 21:53:22 +0000

This two-day in-person symposium brings together researchers, clinicians, infrastructure providers, and innovators to explore how data science and digital platforms are transforming healthcare and health research.

Event | Seminar: Computer-based Predictions of RNA Structures: Where do we stand?

rachel.mutombo@mcgill.ca — Wed, 03 Sep 2025 13:59:00 +0000

Join D2R for this hybrid seminar with Professor Eric Westhof from University of Strasbourg

Seminar Series | Computer-based Predictions of RNA Structures: Where do we stand?

rachel.mutombo@mcgill.ca — Tue, 02 Sep 2025 14:26:22 +0000

Join D2R for this hybrid seminar with Professor Eric Westhof from University of Strasbourg where he will discuss RNA-Puzzles and the advances in RNA 3D structure prediction

News | David Bujold (C3G) appointed Co-Lead of GA4GH Discovery Work Stream

roberta.santangelo@mcgill.ca — Thu, 04 Sep 2025 12:43:45 +0000

The Global Alliance for Genomics and Health (GA4GH) has announced new leadership across several initiatives, including the appointment of David Bujold, Data Team Lead at the Canadian Centre for Computational Genomics (C3G)and Bioinformatics Manager at 91ֱ��’s Victor Phillip Dahdaleh Institute of Genomic Medicine, as Co-Lead of the Discovery Work Stream.

Call for Letters of Intent: Translational Impact Research Program | Cycle 2

rachel.mutombo@mcgill.ca — Tue, 26 Aug 2025 13:31:17 +0000

D2R | DNA to RNA is launching the next round of funding for the Translational Impact Research (TIR) program. This program supports a select few large-scale translational research projects in RNA-based therapeutics which are expected to have a measurable impact on the health of Canadians. Projects must address the D2R Initiative’s strategic priorities and priority disease areas: oncology, rare diseases, infectious diseases, cardiovascular and cardiometabolic diseases.

Applicant Eligibility:

This competition is open to:

Call for Applications: International Partnerships Program

roberta.santangelo@mcgill.ca — Tue, 12 Aug 2025 20:11:02 +0000

D2R | DNA to RNA is launching the International Partnerships Program (IPP) to strengthen large-scale, multi-institutional collaborations with leading global organizations. This strategic funding program supports partnerships that align with D2R’s mission, offer complementary expertise, and provide enriched, multidisciplinary training environments. The program will prioritize initiatives with strong institutional commitment, alignment with D2R’s research priorities, and potential for high global impact.

Call for Applications: D2R Award in Genomic Medicine and Indigenous Health

roberta.santangelo@mcgill.ca — Mon, 28 Jul 2025 18:39:24 +0000

To mark the 25th anniversary of Génome Québec, 91ֱ��’s DNA to RNA (D2R) Initiative is launching a special call for applications for the D2R Award in Genomic Medicine and Indigenous Health. This one-time $25,000 award recognizes excellence and supports inclusive, high-impact research in these fields.

Research | Viral DNA sequences in the human genome may help control gene activity, new study shows

roberta.santangelo@mcgill.ca — Tue, 29 Jul 2025 14:32:51 +0000

Long dismissed as “junk,” viral fragments buried in human DNA may help regulate our genes, according to a new international study co-led by Guillaume Bourque, professor in 91ֱ��’s Department of Human Genetics, D2R-funded researcher and member of the D2R Research Steering Committee and Executive (RSC). The findings offer new insights into what makes us human, 25 years after the human genome was first mapped.

Industry Insights with HDT Bio

emily.cholette2@mcgill.ca — Wed, 09 Jul 2025 18:23:59 +0000

Application of LION/repRNA to develop vaccines and therapies for infectious diseases and cancer